|
James
Abbruzzese, MD
Chairman, GI Oncology
M.D. Anderson Cancer Center
Markus
Büchler, MD
Chairman, Surgery
Heidelberg University, Germany
Ralph
Hruban, MD
Director, GI / Liver
Pathology
Johns Hopkins University
Eileen
O'Reilly, MD
Assistant Professor
Memorial Sloan-Kettering
Margaret
Tempero, MD
Chief, Medical Oncology
University of California - SF
How
to Use This Site
Professor Eileen O'Reilly
has co-authored “100 Questions and Answers About Pancreatic
Cancer” as published by Jones
& Bartlett. More information about this practical book,
including the means to buy it directly from the Publisher’s
website ($19.95), is found at the following link:
More Information
In Remembrance
Walter Leaman
Gary
Lorenzen
R. Gerald
Markle |
|
Frequently
Asked Questions on Pancreatic Cancer
Answers to questions about pancreatic cancer such as Where
can I find more information on hospice and end of life issues? learn more click
here...
Pancreatic
Cancer Clinical Trials Database
The world's largest listing of clinical
trials for pancreatic cancer
Examples include:
A
Phase III Trial Evaluating Both Erlotinib and Chemoradiation
as Adjuvant Treatment for Patients With Resected Head of Pancreas
Adenocarcinoma.
A Prospective, Multicenter, Randomized,
Double-Blind, Placebo-Controlled, 2-Parallel Group, Phase III
Study to Compare Efficacy and Safety of Masitinib 9 mg/kg/Day
in Combination With Gemcitabine Compared to Placebo in Combination
With Gemcitabine in Treatment of Patients With Advanced/Metastatic
Pancreatic Cancer.
Pancreatic
Cancer Medical Literature
Information from medical journals, clinical trials and news sources.
Orientation: new pancreatic cancer treatment findings
Examples include:
Do Recurrent and Metastatic Pancreatic
Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?
Norepinephrine-Induced
Invasion by Pancreatic Cancer Cells is Inhibited by Propranolol
Have fun.
Do good.
Click
here
|
|
RAISE AWARENESS
~ RAISE FUNDS
Select one of our
2010 Walks or Runs
Or Dedicate-A-Race and participate anywhere
Toll Free 1-877-ToFightCancer (877-863-4448)
Participate@ToFightCancer.com
|
For more information
and online registration click
here
|
Would you like to speak
with an experienced counselor about how pancreatic cancer is
affecting your life? |
|
Call 1-800-525-3777 for free counseling
on our Cancer Information and Counseling Line (CICL) from 8:30
to 4:30 (U.S. Mountain Time) Monday thru Friday.
This service is for all
who are affected by pancreatic cancer and is provided in collaboration
with the University of Colorado Cancer Center. |
|
|
|
- Neuroendocrine
Pancreatic Cancer Tumors
-
Information on islet-cell
and carcinoid cancers
- Neuroendocrine and Carcinoid Overview
Recent
Neuroendocrine Research Results
Carcinoid & Neuroendocrine
Select Abstracts
Neuroendocrine and Carcinoid
Clinical Trials
Neuroendocrine
and Carcinoid Links
Contribute
to Pancreatica Now & Fight Pancreatic Cancer !
CAPS
3 Study for those at High Risk for Pancreatic Cancer
- Would you
like to speak with a pancreatic cancer survivor?
Call 1-800-433-0464 for a free
service that will place you in contact with a fellow survivor,
or to volunteer to contact someone more recently diagnosed.
This peer-to-peer connection
service is offered in conjunction with the Bloch Cancer Hotline. |
|
Pancreatic
Cancer Survivor Stories
Read these stories
of long-term pancreatic cancer survivors by clicking here
Milo's
Corner for Survivor Research |
|
|
"Pancreatica.org is a site that MUST be searched by anyone
looking for a comprehensive listing of pancreatic cancer clinical
trials. It is well organized, readable and easy to navigate."
Howard Fuller, Medical
Librarian
Stanford University Medical Center |
|
Pancreatic
Cancer Registries
In this age of molecular
biology and armed with new understandings about the role that
genes play in pancreatic cancer, familial registries are increasingly
a powerful resource to help gain a better understanding of the
disease - and hence better detection or treatment possibilities.
There are about fifteen cancer
registries worldwide that are specific to cancer of the pancreas.
For more information please click here
Select
Abstracts for Pancreatic Cancer
 (most recent)
 For
access to all pancreatic cancer abstracts back to 2003, please
click here
A Case of Metastatic Pancreatic
Cancer with a Remarkable Response to Combination Therapy of Gemcitabine
and Adoptive Immune Cell Therapy
Imai N, Takeda K, Utsunomiya
S, Taga M, Kawata N, Ikeda T, Mizutani Y, Hirose K, Ishikawa
T, Yoshida S.
Gan To Kagaku Ryoho. 2010 Mar;37(3):527-9. Nagoya Kyoritsu Hospital,
Japan.
[Link
to Abstract]
Chemotherapy with 5-Fluorouracil,
Cisplatin and Streptozocin for Neuroendocrine Tumours Turner NC, Strauss SJ, Sarker D, Gillmore
R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I,
Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin
ME, Meyer T.
Br J Cancer. 2010 Mar 30;102(7):1106-12. UCL Medical School,
Royal Free Campus, London, UK.
[Link
to Abstract]
Unresectable Locally Advanced
Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy
(Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical
Exploration
Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi
R, Panizzoni G, Febbraro A, Ambrosino G.
Ann Surg Oncol. 2010 Mar 12 [Epub]. San Bortolo Hospital, Vicenza,
Italy.
[Link
to Abstract]
Safety and Efficacy of Single-Day
Gemox Regimen in Patients with Pancreatobiliary Cancer: A Single
Institution Experience
Li J, Merl M, Lee MX,
Kaley K, Saif MW.
Expert Opin Drug Saf. 2010 Mar;9(2):207-13. Yale School of Medicine,
New Haven, Connecticut.
[Link
to Abstract]
Select Links in Pancreatic Cancer
Afinitor (everolimus) Appeared Effective in Phase III Neuroendocrine Trial. Please click here
Carcinoid Syndrome Symptom Assessor. Please click here
Recent News Articles
on Pancreatic Cancer
Pancreatic Cancer
Alliance news summaries click here
Google Newswire click here
Advocacy
for Pancreatic Cancer
Pancreatica.org
continues to support legislative and other effort aimed at increasing
the funding support for pancreatic cancer treatment and research.
more...
- General Information
- Pancreatic cancer is the most
aggressive of the cancers
- Pancreatic cancer causes more
than 1% of all death in the U.S.
- Pancreatic cancer is the least
funded of the major cancers
Cancer is the second most common
cause of death in the developed world, behind cardiovascular
disease. Pancreatic cancer is the fourth most common cause of
cancer mortality (behind lung cancer, colorectal cancer and breast
cancer).
250 people in North America and
Europe will die today from pancreatic cancer. (90,000 deaths
per year).
The U.S. National Cancer Institute
funds pancreatic cancer research at shockingly low levels (year
2005-07 figures). Pancreatic cancer research receives (per mortality):
 15%
of the funding of breast cancer (but causes 82% of the mortality)
17% of the funding of prostate
cancer (but causes more mortality)
41% of the funding of colorectal
cancer (but causes 63% of the mortality)
Supporters
of Our Effort Against Pancreatic Cancer
Compassionate generosity from the philanthropic and business
world
How Are We Doing?
Please give us feedback |